The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing real-world biomarker testing rates in metastatic colon cancer.
 
Shazia Nakhoda
No Relationships to Disclose
 
Mengying Deng
No Relationships to Disclose
 
Pritish Iyer
No Relationships to Disclose
 
Elizabeth A. Handorf
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Rishi Jain
No Relationships to Disclose
 
Neal J. Meropol
Employment - Flatiron Health; Flatiron Health; Flatiron Health; Flatiron Health
Stock and Other Ownership Interests - Flatiron Health; Flatiron Health; Flatiron Health; Flatiron Health; Roche Pharma AG; Roche Pharma AG; Roche Pharma AG; Roche Pharma AG
Patents, Royalties, Other Intellectual Property - US Patent (20020031515): Methods of therapy for cancers characterized by over expression of the HER2 receptor protein; US Patent (20020031515): Methods of therapy for cancers characterized by over expression of the HER2 receptor protein; US Patent (20020031515): Methods of therapy for cancers characterized by over expression of the HER2 receptor protein; US Patent (20020031515): Methods of therapy for cancers characterized by over expression of the HER2 receptor protein
 
Efrat Dotan
Honoraria - Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb